CytomX Therapeutics, Inc.

Develops tumor-activated antibody therapeutics for more targeted, less toxic cancer treatments.

CTMX | NDAQ

Overview

Corporate Details

ISIN(s):: US23284F1057
LEI:
Country:: United States of America
Address:: 151 OYSTER POINT BLVD., 94080 SOUTH SAN FRANCISCO
Website:: https://cytomx.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company dedicated to developing a novel class of investigational antibody therapeutics. The company's core technology is its proprietary Probody® platform, which is designed to create conditionally activated biologics. These therapeutics remain masked and inactive in healthy tissue but are activated specifically within the tumor microenvironment. This approach aims to enhance the therapeutic window, enabling more potent and targeted anti-cancer treatments with potentially reduced toxicity. CytomX is advancing a deep pipeline of Probody therapeutics, both independently and through strategic collaborations, to bring new treatment options to cancer patients.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all CytomX Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for CytomX Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for CytomX Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
CORESTEMCHEMON Inc. Develops stem cell therapies & provides preclinical CRO services to pharma & biotech.	South Korea	166480
Corline Biomedical AB Develops heparin-based coatings for medical device biocompatibility and regenerative medicine.	Sweden	CLBIO
CorMedix Inc. Develops a catheter lock solution to prevent bloodstream infections in hemodialysis patients.	United States of America	CRMD
Cosma Spolka Akcyjna Produces natural hemp supplements and pharmaceutical raw materials for retail & wholesale markets.	Poland	COS
COSMO Pharmaceuticals N.V. Specialty pharma for gastroenterology/dermatology, offering colon treatments & manufacturing services.	Netherlands	COPN
Cosmos Health Inc. A global healthcare firm developing & distributing nutraceuticals, generics, and OTC medications.	United States of America	COSM
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. Biotech firm developing cell therapies for regenerative medicine and immunotherapy applications.	United States of America	CELZ
CRESCENT BIOPHARMA, INC. A biotech company developing bispecific antibody therapies to treat solid tumors.	United States of America	CBIO
Crinetics Pharmaceuticals, Inc. Develops novel therapeutics for rare endocrine diseases and related tumors.	United States of America	CRNX
CRISPR Therapeutics AG Develops transformative CRISPR gene-based medicines for diseases like sickle cell.	United States of America	CRSP